[go: up one dir, main page]

AR051984A1 - Compuestos heterociclicos como inhibidores del factor viia - Google Patents

Compuestos heterociclicos como inhibidores del factor viia

Info

Publication number
AR051984A1
AR051984A1 ARP050105117A ARP050105117A AR051984A1 AR 051984 A1 AR051984 A1 AR 051984A1 AR P050105117 A ARP050105117 A AR P050105117A AR P050105117 A ARP050105117 A AR P050105117A AR 051984 A1 AR051984 A1 AR 051984A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
heterocycle
carbon atoms
heteroatoms selected
Prior art date
Application number
ARP050105117A
Other languages
English (en)
Inventor
Peter W Glunz
Nicholas Wurtz
Xuhong Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR051984A1 publication Critical patent/AR051984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que inhiben las serina proteasa. En particular se dirigen a compuestos heterocíclicos, que son utiles como inhibidores selectivos de las enzimas serina proteasa de la cascada de coagulacion; por ejemplo trombina, factor VIIa, factor Xa, factor Xia, factor IXa, y/o calicreína de plasma. En particular, compuestos que son inhibidores del factor VIIa. También composiciones farmacéuticas que comprenden estos compuestos y métodos de uso de los mismos. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), o un estereoisomero, tautomero, sal, solvato o profármaco farmacéuticamente aceptable de los mismos, en donde: X se selecciona del grupo de formulas (2) y (3), en donde X1, X2, X3, X4, X5, X6, X7, X8, y X9 son independientemente CR6 o N, con la condicion de que X no tenga más de tres átomos de nitrogeno en el anillo; R6 es, independientemente cada vez que se presenta, H, -(CH2)r-ORa, F, Cl, Br, OCF3, CN, NO2, -NRbRc, -(CF2)rCF3, o alquilo C1-6 sustituido con 0-2 Re; R8 es fenilo sustituido con 0-5 R8b, o un heteroarilo de 5 hasta 6 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S, en donde el heteroarilo es sustituido con 0-5 R8b; R8a es H alquilo C1- 4; R8b es, independientemente cada vez que se presente, H, -(CH2)r-ORa, SRa, F, Cl, Br, I, CN, NO2, -OCF3, -NRbRc, -C(O)Ra, -C(O)ORa, -NRdC(O) Ra, -C(O)NRcRd, -SO2NRcRd, -NRcSO2NRcRd, -NRcSO2R1a, -NRcSO2CF3, -S(O)2CF3, -S(O)2Ra1, -S(O)R1a, - (CF2)rCF3, alquilo C1-6 sustituido con 0-2 Re, alquenilo C2-6 sustituido con 0-2 Re, alquinilo C2-6 sustituido con 0-2 Re, -(CH2)r-cicloalquiloC3-7 sustituido con 0-2 Re, -(CH2)r-cicloalqueniloC3-7 sustituido con 0-2 Re, -(CH2)r-feniloC3-7 sustituido con 0-4 Rf, -(CH2)r-heteroarilo de 5 hasta 6 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p, o -(CH2)r-heterociclo de 4 hasta 7 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p, en donde el heteroarilo y heterociclo son sustituidos con 0-4 Rf; alternativamente, dos grupos R8b en dos átomos de carbono adyacentes pueden tomarse junto con los átomos de carbono a los cuales se enlazan, para formar un carbociclo o heterociclo de 5 hasta 7 miembros que comprende: átomos de carbono y 0-4 heteroátomos seleccionados de N, O y S(O)p, en donde el carbociclo y heterociclo son sustituidos con 0-3 Rf; la formula (4) es un heteroarilo de 5 hasta 6 miembros que incluye el átomo de nitrogeno que se muestra en el anillo, que comprende: átomos de carbono y 0-3 heteroátomos adicionales seleccionados de N, NR11, NR11a, O, y S, y el anillo Z es sustituido con 0-1 R12 y 0-3 R12a; con la condicion de que: las tres valencias del átomo de nitrogeno mostradas en el anillo Z se satisfacen por los enlaces de anillo; opcionalmente, el anillo Z se fusiona a un carbociclo o heterociclo de 5 hasta 10 miembros que comprende: átomos de carbono y 0-4 heteroátomos adicionales seleccionados de N, NR11, NR11a, O, y S(O)p, en donde el carbociclo y heteroarilo son complemente insaturados o parcialmente saturados y son sustituidos con 0-1 R12 y 0-3 R12a; R11 y R11a son, independientemente cada vez que se presentan, H, alquilo C1-6 sustituido con 0-4 Re, -alquiloC0-4-ariloC6-10, -alquiloC0-4-heteroarilo de 5 hasta 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p); en donde el arilo y heteroarilo son sustituidos con 0-4 Rf; R12 y R12a son, independientemente cada vez que se presentan, H, -(CH2)r-ORa, F, Cl, Br, I, CN, NO2, -OCF3, -NRbRc, -C(O)Ra, -C(O)ORa, -NRdC(O)Ra, -C(O)NRcRd, -SO2NRcRd, -NRcSO2NRcRd, -NRcSO2R1a, -NRcSO2CF3, -S(O)2CF3, - S(O)2Ra1, -S(O)R1a, -(CF2)rCF3, alquilo C1-6 sustituido con 0-2 Re, alquenilo C2-6 sustituido con 0-2 Re, alquinilo C2-6 sustituido con 0-2 Re, -(CH2)r- cicloalquiloC3-7 sustituido con 0-2 Re, -(CH2)r-cicloalqueniloC3-7 sustituido con 0-2 Re, -(CH2)r- fenilo sustituido con 0-4 Rf, -(CH2)r- naftilo sustituido con 0-4 Rf, -(CH2)r-heteroarilo de 5 hasta 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p, o -(CH2)r-heterociclo de 4 hasta 8 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p; en donde el heteroarilo y heterociclo son sustituidos con 0-4 Rf; R13 es -C(=NRh)NRbRc o -CRaRaNRbRc; R14 es -NRbRc, H, alquilo C1-4; R1a es, independientemente cada vez que se presenta, alquilo C1-6 sustituido con 0-4 Rj, -(CH2)r- cicloalquilo C3-7 sustituido con O-4 Rf, -(CH2)r-ariloC6-10, o -(CH2)r-heterociclo de 5 hasta 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de NRb, O, y S(O)p; en donde el arilo y heterociclo son opcionalmente sustituidos con 0-4 Rf; Ra es, independientemente cada vez que se presenta, H o R1a; Rb es, independientemente cada vez que se presenta, H, alquilo C1-6, -(CH2)r-fenilo, alquiloC1-6C(O)-, cicloalquiloC3-6-alquiloC0-4-C(O)-, ariloC6-10-alquiloC0-4-C(O)-, heteroarilo de 5 hasta 10 miembros- alquiloC0-4-C(O)-, alquiloC1-6-NHC(O)-, alquiloC1-6-NHC(O)-, ariloC6-10-alquiloC0-4-NHC(O)-, heteroarilo de 5 hasta 10 miembros- alquiloC0-4-NHC(O)-, alquiloC1-6-S(O)2-, ariloC6-10-alquiloC0-4-S(O)2-, o heteroarilo de 5 hasta 10 miembros-alquiloC0-4-S(O)2-, en donde el fenilo, arilo y heteroarilo son sustituidos con 0-2 Rf; el heteroarilo comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p; Rc es, independientemente cada vez que se presenta, H, alquilo C1-6 sustituido con 0-3 Rj, o -(CH2)n- fenilo sustituido con 0-3 Rj; alternativamente, Rb y Rc, cuando se enlazan al mismo átomo de nitrogeno, pueden tomarse junto con el átomo de nitrogeno para formar un heterociclo de 4 hasta 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Rf; Rd es, independientemente cada vez que se presenta, H, alquilo C1-6, -(CH2)r-carbociclo C3-10 sustituido con 0-3 Rf, o un -(CH2)r-heterociclo de 5 hasta 12 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Rf; alternativamente, Rc y Rd, cuando se unen al mismo átomo de nitrogeno, puede tomarse junto con el átomo de nitrogeno para formar un heterociclo de 4 hasta 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p, en donde el heterociclo es sustituido con 0-3 Rf; Re es, independientemente cada vez que se presenta, =O, ORa, F, Cl, Br, I, CN, NO2, -OCF3, - NRbRc, -C(O)Ra, -C(O)ORa, -NRdC(O)Ra, -C(O)NRcRd, -SO2NRcRd, -NRcSO2NRcRd, - NRcSO2R1a, -NRcSO2CF3, -S(O)2CF3, -S(O)2Ra1, -S(O)R1a, -(CF2)rCF3, -(CH2)r-carbocicloC3-10 sustituido con 0-3 Rf, o un -(CH2)r-heterociclo de 5 hasta 12 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p, en donde el heterociclo es sustituido con 0-3 Rf; Rf es, independientemente cada vez que se presenta, H, =O, -(CH2)rORg, F, Cl, Br, I, CN, NO2, -OCF3, -NRcRc, -C(O)Rg, -C(O)ORg, -NRcC(O) Rg, -C(O)NRcRc, -SO2NRcRc, -NRcSO2NRcRc, -NRcSO2-alquiloC1-4, - NRcSO2CF3, -NRcSO2-fenilo, -S(O)2CF3, -S(O)p-alquiloC1-4, - S(O)p-fenilo, -(CF2)rCF3, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -(CH2)r-carbocicloC3-10 sustituido con 0-3 Rj, o un -(CH2)r- heterociclo de 5 hasta 12 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p, en donde el heterociclo es sustituido con 0-3 Rj; Rg es, independientemente cada vez que se presenta, H, alquilo C1-6, o -(CH2)n-fenilo; Rh es, independientemente cada vez que se presenta, H, OH, alquilo C1-6, alcoxi C1-4, ariloC6-10-alcoxiC1-4, -(CH2)r-fenilo, alquiloC1-6C(O)-, ariloC6-10-alquiloC0-4-C(O)-, cicloalquiloC3-6-alquiloC0-4-C(O)-, heteroarilo de 5 a 10 miembros-alquiloC0-4-C(O)-, alquiloC1-4-OC(O)-, ariloC6-10-alquiloC1-4- OC(O)-, alquiloC1-4-C(O)O-alquiloC1-4-OC(O)-, ariloC6-10-C(O)O-alquiloC1-4-OC(O)-, heteroarilo de 5 a 10 miembros-alquiloC0-4-OC(O)-, alcoxi C1-4, alquiloC1-4C(O)O-, o ariloC6-10-alquiloC0-4-C(O)O-; en donde el fenilo, arilo y heteroarilo son sustituidos con 0-3 Rf; el heteroarilo comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p; Ri es, independientemente cada vez que se presenta, ORa, F, Cl, Br, I, CN, NO2, -OCF3, -NRbRc, -C(O)Ra, -C(O)ORa, -NRdC(O)Ra, - C(O) NRcRd, -SO2NRcRd, -NRcSO2NRcRd, -NRcSO2alquiloC1-4, -NRcSO2CF3, -NRcSO2-fenilo, -S(O)2CF3, -S(O)p-alquiloC1-4, -S(O)p-fenilo, -(CF2)rCF3, -(CH2)r-carbocicloC3-10 sustituido con 0-3 Rf, o un -(CH2)r-heterociclo de 5 hasta 12 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p, en donde el heterociclo es sustituido con 0-3 Rf; Rj es, independientemente cada vez que presenta, H, =O, -(CH2)rORg, F, Cl, Br, I, CN, NO2, -OCF3, -NRgRg, -C(O)Rg, - C(O)ORg, -NRgC(O)Rg, -C(O)NRgRg, - SO2NRgRg, -NRgSO2NRgRg, -NRgSO2-alquiloC1-4, -NRgSO2CF3, -NRgSO2-fenilo, -S(O)2CF3, -S(O)p-alquiloC1-4, -S(O)p-fenilo, -(CF2) rCF3, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquiloC1-6C(O)-, cicloalquiloC3-6- alquiloC0-4-C(O)-, ariloC6-10-alquiloC0-4-C(O)-, heteroarilo de 5 a 19 miembros-alquiloC0-4-C(O)-, alquiloC1-6-NHC(O)-, alquiloC1-6-NHC(O)-, ariloC6-10-alquiloC0-4-NHC(O)-, heteroarilo de 5 a 10 miembros-alquiloC0-4-NHC(O)-, alquiloC1-6-S(O)2-, ariloC6-10-alquiloC0-4-S(O)2-, heteroarilo de 5 a 10 miembros-alquiloC0-4-S(O)2-, -(CH2)r-carbocicloC3-10, o un-(CH2)r-heterociclo de 5 hasta 12 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O y S(O)p, en donde el heteroarilo comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, O, y S(O)p; n, cada vez que se presenta, se selecciona de 0, 1, 2, 3, y 4; p, cada vez que se presenta, se selecciona de 0, 1 y 2; y r, cada vez que se presenta, se selecciona de 0, 1, 2, 3, y 4.
ARP050105117A 2004-12-08 2005-12-07 Compuestos heterociclicos como inhibidores del factor viia AR051984A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63429004P 2004-12-08 2004-12-08
US73292605P 2005-11-02 2005-11-02

Publications (1)

Publication Number Publication Date
AR051984A1 true AR051984A1 (es) 2007-02-21

Family

ID=36578487

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105117A AR051984A1 (es) 2004-12-08 2005-12-07 Compuestos heterociclicos como inhibidores del factor viia

Country Status (9)

Country Link
US (1) US7576098B2 (es)
EP (1) EP1828152B1 (es)
AR (1) AR051984A1 (es)
AT (1) ATE405553T1 (es)
DE (1) DE602005009252D1 (es)
ES (1) ES2310861T3 (es)
PE (1) PE20061153A1 (es)
TW (1) TW200621229A (es)
WO (1) WO2006062972A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041119A1 (ja) * 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
TW200637843A (en) 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
WO2007002313A2 (en) * 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
EP2000465B1 (en) 2006-03-24 2010-12-15 Eisai R&D Management Co., Ltd. Triazolone derivative
JP2009539873A (ja) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 抗凝固剤として有用な第ＶＩＩａ因子インヒビターとしての２−アミノカルボニルフェニルアミノ−２−フェニルアセトアミド類
EP2125753A1 (en) 2006-12-29 2009-12-02 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds having crf antagonistic activity
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
US8212047B2 (en) * 2007-09-20 2012-07-03 Exxonmobil Chemical Patents Inc. Methods for preparation of pyridylamines
JPWO2009038157A1 (ja) * 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２，３−ジヒドロ−イミノイソインドール誘導体
WO2010065717A1 (en) 2008-12-05 2010-06-10 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
JP2010150200A (ja) * 2008-12-25 2010-07-08 Tosoh Corp イミダゾール化合物およびその製造方法
KR20120004483A (ko) 2009-04-02 2012-01-12 메르크 파텐트 게엠베하 오토탁신 저해제
US20160257668A1 (en) 2013-10-07 2016-09-08 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
WO2015123091A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
US10093683B2 (en) 2014-04-22 2018-10-09 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2015171527A1 (en) * 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN104496926B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一类含二烯四氮唑结构的化合物、其制备方法和用途
EP3909509A1 (en) 2015-08-13 2021-11-17 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
MX2018005045A (es) 2015-10-29 2018-08-01 Merck Sharp & Dohme Inhibidores de factor xia.
EP3371162B1 (en) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN111557899B (zh) * 2020-04-30 2023-02-21 北华大学 一种治疗角膜炎的药物及其制备方法
CN114621101A (zh) * 2020-12-11 2022-06-14 李冰坚 一种3,5-二甲基-1,2-苯二胺二盐酸盐的精制方法
CN114621096A (zh) * 2020-12-11 2022-06-14 余购粮 一种3,5-二甲基-1,2-苯二胺二盐酸盐的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
PT921116E (pt) * 1997-12-04 2003-11-28 Hoffmann La Roche Derivados de n-(4-carbamimido-fenil)-glicinamida
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
PL348436A1 (en) * 1998-12-14 2002-05-20 Hoffmann La Roche Phenylglycine derivatives
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
PE20020384A1 (es) * 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
AU2002227269A1 (en) * 2000-11-07 2002-06-03 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US6713467B2 (en) * 2000-11-07 2004-03-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
JP2004522759A (ja) 2001-02-02 2004-07-29 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 抗血栓性化合物、その製法及び医薬組成物としての使用
US20020151534A1 (en) * 2001-02-02 2002-10-17 Ries Uwe Joerg Antithrombotic compounds
WO2002064598A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
ATE280164T1 (de) 2001-02-14 2004-11-15 Warner Lambert Co Benzothiadiazine als matrix metallproteinase inhibitoren
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
MXPA04004219A (es) * 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2003279182A1 (en) 2002-06-19 2004-01-06 Bristol-Myers Squibb Company Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor viia-associated conditions
US7094783B2 (en) * 2002-06-26 2006-08-22 Bristol-Myers Squibb Company Bicyclic pyrimidinones as coagulation cascade inhibitors
AU2003243657A1 (en) * 2002-06-26 2004-01-19 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
WO2004072102A2 (en) * 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Benzene acetamide compounds useful as serine protease inhibitors
EP1594505A4 (en) * 2003-02-11 2008-08-13 Bristol Myers Squibb Co PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
US7247654B2 (en) * 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
TW200637843A (en) * 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
WO2007002313A2 (en) * 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Also Published As

Publication number Publication date
EP1828152A2 (en) 2007-09-05
TW200621229A (en) 2006-07-01
WO2006062972A3 (en) 2006-08-24
ES2310861T3 (es) 2009-01-16
EP1828152B1 (en) 2008-08-20
US20060211720A1 (en) 2006-09-21
DE602005009252D1 (de) 2008-10-02
WO2006062972A2 (en) 2006-06-15
PE20061153A1 (es) 2006-10-27
ATE405553T1 (de) 2008-09-15
US7576098B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
AR051984A1 (es) Compuestos heterociclicos como inhibidores del factor viia
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
CL2008003384A1 (es) Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CY1109748T1 (el) Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR086095A1 (es) Derivados de nucleosidos 2’-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
UY28500A1 (es) Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
AR054186A1 (es) Derivados de tetrahidroindazolona y tetrahidroindolona
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
MX2011012155A (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c.
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
ES2530815T3 (es) Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas
AR085352A1 (es) Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
AR039475A1 (es) 6-alquiliden-penems triciclicos como inhibidores de beta-lactamasa
UY28924A1 (es) Compuestos antibioticos particularmente conteniendo anillos de oxazolidinona y isoxazolina sustituidos, composiciones farmaceuticas, preparación, intermedios para ello y su uso terapeutico.
AR037976A1 (es) Sulfonamidas que contienen fenilo sustituido con grupos heterociclicos, una composicion farmaceutica, un producto combinado con un agente antirretroviral y el uso de las mismas para la fabricacion de un medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure